Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | NPC1 | O15118 | 4/20 | 0.78 |
| ▸ | RAB9A | P51151 | 4/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.57 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | TEK | Q02763 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22001460 | 0.88 | NPC1 (0.74) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL21360469 | 0.88 | ALDH1A1 (1.00) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL9587009 | 0.88 | NPC1 (1.00) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL1430465 | 0.88 | NPC1 (0.74) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL18952383 | 0.84 | ALDH1A1 (0.69) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL18952253 | 0.84 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL18952249 | 0.84 | NPC1 (0.73) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL29614093 | 0.83 | RAB9A (0.68) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL7222027 | 0.80 | NTRK1 (0.58) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL29953652 | 0.80 | NPC1 (0.53) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2011113606-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2011-09-22 | — | — | WO | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20080139594-A1 | Imidazo-Pyridine Derivatives For Use In The Treatment of Herpes Viral Infection | GUDMUNDSSON KRISTJAN | 2008-06-12 | — | — | US | disclosed |
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-7244740-B2 | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070135451-A1 | Imidazo[1,2-a]Pyridine Derivatives for Treatment Of Herpes Viral Infections | GUDMUNDSSON KRISTJAN S | 2007-06-14 | — | — | US | disclosed |
| US-7186714-B2 | Imidazo[1,2-α]pyridine derivatives for the prophylaxis and treatment of herpes viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | ALDH1A1 269/4885NPC1 372/4885RAB9A 1870/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | ALDH1A1 269/4885NPC1 372/4885RAB9A 1870/4885 |
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | ALDH1A1 1043/4885NPC1 3971/4885RAB9A 3412/4885 |
| US-20070135451-A1 | Imidazo[1,2-a]Pyridine Derivatives for Treatment Of Herpes Viral Infections | IRF3, IFNAR1, IL2 | ALDH1A1 404/4885NPC1 1118/4885RAB9A 1481/4885 |
| US-20080139594-A1 | Imidazo-Pyridine Derivatives For Use In The Treatment of Herpes Viral Infection | IRF3, RPL5, RPL35 | ALDH1A1 1050/4885NPC1 983/4885RAB9A 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.